|
|
|
company overview
|
OxThera is a clinical stage biotechnology company with its first product in phase III. The company is based in Sweden (Uppsala) and Florida (Gainesville). The company develops products, based on its cell- and enzyme based proprietary technologies, for metabolic disorders based on excess oxalate from endogenous and exogenous sources. OxThera will market and sell its orphan drug products to treat and prevent hyperoxaluria and kidney stones in indications such as Primary and Enteric Hyperoxaluria.
|
|
|